Central nervous system adverse events of immune checkpoint inhibitors
Authors:
- 14 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 37 (3) , 345-352
Abstract
Purpose of review: Immune checkpoint inhibitors (ICI) may trigger immune-related adverse events which rarely affect the central nervous system (CNS-irAEs). Over the past few years, cumulative data have led to the characterization of well defined syndromes with distinct cancer and antibody associations as well as different outcomes. Recent findings: The most frequent CNS-irAE is encephalitis, which includes three main groups: meningoencephalitis, a nonfocal syndrome usually responsive to corticosteroids; limbic encephalitis, associated with high-risk paraneoplastic neurological syndromes (PNS) antibodies (e.g. anti-Hu, anti-Ma2) and neuroendocrine cancers, characterized by poor treatment response and outcomes; and cerebellar ataxia, with variable outcomes (worse when high-risk PNS antibodies are detected). Additionally, a diffuse encephalopathy without inflammatory findings, with poor response to corticosteroids and high mortality has been described. The spectrum of CNS-irAEs also includes meningitis, myelitis, and rarer presentations. A subset of CNS-irAEs (i.e. limbic encephalitis and/or rapidly progressive cerebellar ataxia) is undistinguishable from ICI-naïve PNS. Summary: The clinical and outcomes diversity of CNS-irAEs suggests different pathogenic mechanisms, which need to be understood to establish more effective and specific treatment modalities. It is crucial to identify biomarkers able to predict which patients will experience severe CNS-irAEs, to anticipate their diagnosis, and to predict long-term outcomes.Keywords
This publication has 53 references indexed in Scilit:
- Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapyJournal of Neurology, 2023
- Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicityCancer Medicine, 2023
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint InhibitorsJAMA Neurology, 2022
- Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practiceNeurological Sciences, 2022
- Encephalitis Induced by Immune Checkpoint InhibitorsJAMA Neurology, 2021
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS databaseJournal of Neuro-Oncology, 2021
- Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing SpectrumAnnals of Neurology, 2020
- Multiple sclerosis outcomes after cancer immunotherapyClinical and Translational Oncology, 2019
- A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitorsInternational Journal of Cancer, 2019